887266-99-1Relevant articles and documents
Discovery of 5-(2-chloro-4′-(1H-imidazol-1-yl)-[1,1′-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD
Muthukaman, Nagarajan,Deshmukh, Sanjay,Tondlekar, Shital,Tambe, Macchindra,Pisal, Dnyandeo,Sarode, Neelam,Mhatre, Siddharth,Chakraborti, Samitabh,Shah, Daisy,Bhosale, Vikram M.,Kulkarni, Abhay,Mahat, Mahamad Yunnus A.,Jadhav, Satyawan B.,Gudi, Girish S.,Khairatkar-Joshi, Neelima,Gharat, Laxmikant A.
, p. 3766 - 3773 (2018/10/20)
Endogenous nitrosothiols (SNOs) including S-nitrosoglutathione (GSNO) serve as reservoir for bioavailable nitric oxide (NO) and mediate NO-based signaling, inflammatory status and smooth muscle function in the lung. GSNOR inhibition increases pulmonary GS
IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
-
Page/Page column 75; 80, (2016/04/20)
The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).
